Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients with Gallbladder Carcinoma

Cancer Manag Res. 2020 May 11:12:3271-3283. doi: 10.2147/CMAR.S243326. eCollection 2020.

Abstract

Background: This study was designed to investigate the prognostic value of the lymphocyte to monocyte ratio (LMR) in patients with gallbladder carcinoma (GBC).

Patients and methods: We retrospectively enrolled 154 consecutive GBC patients from 2005 to 2017 in this study. The LMR of preoperative blood samples was calculated by dividing the lymphocyte count by the monocyte count. A receiver operating characteristic (ROC) curve was employed to identify the optimal cut-off value of the LMR in the determination of overall survival (OS). The Kaplan-Meier method was utilized to assess OS, and the Log rank test was employed to compare survival differences. Univariate and multivariate Cox regression analyses were conducted to detect independent prognostic indicators.

Results: The optimal cut-off point for the LMR was 4.76 according to the ROC curve. Patients ≤60 years old with an LMR ≤4.76 experienced significantly worse OS than those with an LMR >4.76 (hazard ratio (HR): 0.399, 95% confidence interval (CI): 0.265-0.602, P<0.001); however, the prognostic value of the LMR was not determined in patients >60 years old or among the entire study cohort (both P>0.05). Significantly poorer OS was observed in patients >60 years with an LMR ≤4.21 compared to those with an LMR >4.21 (HR: 1.830, 95% CI: 1.129-2.967, P=0.014). Multivariate Cox regression analysis indicated that both the high and low LMR cut-off values were independent risk factors for OS (HR: 0.272, 95% CI: 0.105-0.704, P=0.007; HR: 0.544, 95% CI: 0.330-0.895, P=0.017).

Conclusion: The LMR is an independent prognostic indicator for GBC patients, the cut-off value of which is age dependent.

Keywords: LMR; biomarker; gallbladder cancer; lymphocyte to monocyte ratio; prognosis; survival.

Grants and funding

This study was supported by grants from the Beijing Natural Science Foundation (No. L172055), Beijing Municipal Science & Technology Commission research fund (No. Z171100000417004), WBE Liver Fibrosis Foundation (CFHPC 2020021), and Beijing Dongcheng District outstanding talent funding project.